Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 12/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 7/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14975990 | 0.99 | PARP1 (0.98) | PARP1PARP3PARP2 | |
| SCHEMBL14977078 | 0.91 | PARP1 (1.00) | PARP1PARP3PARP2 | |
| Hydrochloric Acid SCHEMBL14977072 | 0.90 | PARP1 (0.97) | PARP1PARP3PARP2 | |
| SCHEMBL14976681 | 0.89 | PARP1 (1.00) | PARP1PARP3PARP2 | |
| SCHEMBL30417578 | 0.89 | PARP1 (1.00) | PARP1PARP3PARP2 | |
| SCHEMBL14977263 | 0.89 | PARP1 (1.00) | PARP1PARP3PARP2 | |
| Hydrochloric Acid SCHEMBL14976519 | 0.88 | PARP1 (0.98) | PARP1PARP3PARP2 | |
| Hydrochloric Acid SCHEMBL14976967 | 0.88 | PARP1 (0.98) | PARP1PARP3PARP2 | |
| SCHEMBL14976385 | 0.88 | PARP1 (1.00) | PARP1PARP3PARP2 | |
| SCHEMBL14977120 | 0.87 | PARP1 (1.00) | PARP1PARP3PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422243-B2 | 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. a corporation (IT) | 2016-08-23 | — | — | US | claimed |
| US-20140336192-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. a corporation | 2014-11-13 | — | — | US | claimed |
| EP-2788328-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-10-15 | — | — | EP | claimed |
| WO-2013076090-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-05-30 | — | — | WO | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| EP-2788328-B1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2018-01-31 | — | — | EP | disclosed |
| WO-2017075052-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017042634-A2 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE | DEL MAR PHARMACEUTICALS (CA) | 2017-03-16 | — | — | WO | disclosed |
| US-9422243-B2 | 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. a corporation (IT) | 2016-08-23 | — | — | US | disclosed |
| US-9422243-B2 | 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. a corporation (IT) | 2016-08-23 | — | — | US | disclosed |
| US-20140336192-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. a corporation | 2014-11-13 | — | — | US | disclosed |
| US-20140336192-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. a corporation | 2014-11-13 | — | — | US | disclosed |
| US-20140336192-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. a corporation | 2014-11-13 | — | — | US | disclosed |
| EP-2788328-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013076090-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013076090-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP3 932/4885PARP2 422/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | PARP1 418/4885PARP3 932/4885PARP2 422/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP3 932/4885PARP2 422/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | PARP1 418/4885PARP3 932/4885PARP2 422/4885 |
| US-20140336192-A1 | 3-PHENYL-ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | PARP1, PARP2, PARP11 | PARP1 1/4885PARP3 4/4885PARP2 2/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | PARP1 248/4885PARP3 639/4885PARP2 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.